Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Use of an in vitro pharmacodynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracis.

Antimicrobial agents and chemotherapy - 1 Jul 2008

Louie A, Heine H S, Kim K, Brown D L, VanScoy B, Liu W, Kinzig-Schippers M, Sörgel F, Drusano G L

Abstract excerpt

Simulating the average non-protein-bound (free) human serum drug concentration-time profiles for linezolid in an in vitro pharmacodynamic model, we characterized the pharmacodynamic parameter(s) of linezolid predictive of kill and for prevention of resistance in Bacillus anthracis. In 10-day dose...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acetamides
Share to Anthrax
Share to Bacillus anthracis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Administration Schedule

Share to In Vitro Techniques

Share to Linezolid

Share to Monte Carlo Method

Share to Oxazolidinones

Source

Open in PubMed Open full text

Identifiers

PMID: 18458134
DOI: 10.1128/AAC.01439-07
PMCID: PMC2443924

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-18458134-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Use of an in vitro pharmacodynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracis.PMID 18458134Read ↗

Use of an in vitro pharmacodynamic model to derive a moxifloxacin regimen that optimizes kill of Yersinia pestis and prevents emergence of resistance.Semantic proximity Read ↗

Population Pharmacokinetics of Linezolid in Adults with Pulmonary TuberculosisSemantic proximity Read ↗

Population pharmacokinetics and dose evaluations of linezolid in the treatment of multidrug-resistant tuberculosisSemantic proximity Read ↗

Rising resistance to linezolid among critically ill patients calls for model-informed precision dosing in the empirical settingSemantic proximity Read ↗

Modelling biphasic killing of fluoroquinolones: guiding optimal dosing regimen design.Semantic proximity Read ↗

A Physiologically Based Pharmacokinetic Model of Isoniazid and Its Application in Individualizing Tuberculosis Chemotherapy.Semantic proximity Read ↗

Clinical Population Pharmacokinetics and Toxicodynamics of LinezolidSemantic proximity Read ↗

Establishing a framework for human dose prediction in anti-tuberculosis drug developmentSemantic proximity Read ↗

Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy.Semantic proximity Read ↗

The role of the time-kill kinetics assay as part of a preclinical modeling framework for assessing the activity of anti-tuberculosis drugs.Semantic proximity Read ↗

Systematic Evaluation of High-Throughput PBK Modelling Strategies for the Prediction of Intravenous and Oral Pharmacokinetics in HumansSemantic proximity Read ↗

Clinical implications of pharmacokinetics and pharmacodynamics of fluoroquinolones.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.